Table 1.
Demographic and clinical data for 271 patients with rheumatoid arthritis included in a real-life study investigating first-line antitumour necrosis factor therapy.
| Characteristic | N |
|---|---|
| Sex | |
| Female | 219 (80.8) |
| Male | 52 (19.2) |
| Age, years | 54.5 ± 13.2 |
| Disease duration, years | 8.8 ± 11.1 |
| Early arthritis (<2 years) | 66 (24.3) |
| Positive rheumatoid factor | 173 (63.8) |
| Anti-TNF therapy in combination with csDMARDs | 193 (71.2) |
| Anti-TNF monotherapy | 78 (28.8) |
| Etanercept treatment | 159 (58.7) |
| Adalimumab treatment | 112 (41.3) |
| Prednisone treatment | 137 (50.5) |
| Baseline DAS28 score | 5.2 ± 1.3 |
| Baseline CDAI score | 27.4 ± 14.2 |
| Baseline SDAI score | 28.3 ± 14.7 |
Data presented as n (%) of patients or mean ± SD.
Anti-TNF, antitumour necrosis factor; CDAI, Clinical Disease Activity Index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAS28, 28-joint Disease Activity Score; SDAI, Simplified Disease Activity Index.